
Patients with HER2-positive metastatic breast cancer who received pertuzumab (Perjeta, Roche) as part of their chemotherapy regimen had a significantly longer median survival rate-by almost 16 months-compared with those who only received the trastuzumab/docetaxel regimen, according to a presentation during the 2014 Congress of the European Society for Medical Oncology in Spain.